Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00151203 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00151203 is a Phase 2 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 50 participants.
The verdict
NCT00151203, a Phase 2 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
PRIMARY STUDY OBJECTIVES * To evaluate the efficacy of the combination of clarithromycin (Biaxin®), lenalidomide (Revlimid™), and dexamethasone (Decadron®) as an induction therapy for patients with newly diagnosed multiple myeloma (MM). * To evaluate the safety of the combination of clarithromycin, lenalidomide, and dexamethasone as an induction therapy for patients with newly diagnosed MM. SECONDARY STUDY OBJECTIVES * To examine the role of clarithromycin on the pharmacokinetic properties of dexamethasone and lenalidomide. * To examine the angiogenesis profile in untreated patients and in patients receiving induction therapy.
Interventions
- DRUG Clarithromycin, Lenalidomide, Dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2004-12 |
| Est. Completion | 2020-09-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00151203
The ClinicalTrials.gov registry entry for NCT00151203 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Clarithromycin, Lenalidomide, Dexamethasone is the first listed.
NCT00151203 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00151203 about?
NCT00151203 is a clinical study titled "Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma". PRIMARY STUDY OBJECTIVES * To evaluate the efficacy of the combination of clarithromycin (Biaxin®), lenalidomide (Revlimid™), and dexamethasone (Decadron®) as an induction therapy for patients with newly diagnosed multiple myeloma (MM). * To evaluate the safety of the combination of clarithromycin,...
What is the current status of trial NCT00151203?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2004-12. Estimated completion is 2020-09-29.
What interventions are being tested in trial NCT00151203?
The interventions under investigation include: Clarithromycin, Lenalidomide, Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT00151203?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.